David Comer

Microbiota in health and diseases

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR

Cystic fibrosis

Ivacaftor potentiation of multiple CFTR channels with gating mutations

14,15-Epoxyeicosatrienoic Acid Suppresses Cigarette Smoke Extract-Induced Apoptosis in Lung Epithelial Cells by Inhibiting Endoplasmic Reticulum Stress

Cystic fibrosis genetics: from molecular understanding to clinical application

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial

Respiratory viral infection: a potential “missing link” in the pathogenesis of COPD

Profiling of lung microbiota discloses differences in adenocarcinoma and squamous cell carcinoma

Update on Key Emerging Challenges in Cystic Fibrosis

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Salidroside Attenuates Ventilation Induced Lung Injury via SIRT1-Dependent Inhibition of NLRP3 Inflammasome.

Clinical phenotype of cystic fibrosis patients with the G551D mutation

Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers

Airway epithelial cell apoptosis and inflammation in COPD, smokers and nonsmokers